Arcturus Therapeutics Holdings Inc (NAS:ARCT)
$ 17.9 -0.74 (-3.97%) Market Cap: 484.87 Mil Enterprise Value: 297.15 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 77/100

Arcturus Therapeutics Holdings Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 05:35PM GMT
Release Date Price: $20.89 (+12.55%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. Thank you. Good afternoon, everyone. And welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Arcturus Therapeutics. With us today, we have both Joe Payne, President and Chief Executive Officer; and also Andy Sassine, Chief Financial Officer. With that, I will hand over to Joe to give introduction slides.

Joseph E. Payne
Arcturus Therapeutics Holdings Inc. - Founder, President, CEO & Director

All right. Thank you, Gena. It's good to be with you. It's good to be at a face-to-face conference, it's been a while. And I'm happy to introduce Arcturus Therapeutics to you. First of all, I think it's helpful. It says on the introductory slide, but this is next-generation RNA medicine. So Arcturus is a messenger RNA vaccines and therapeutics company. So both vaccines and therapeutics. And the critical issue, we believe, for vaccines right now, is addressing the dose level, which we believe is too high for messenger RNA vaccines.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot